AWHL Aspira Women's Health Inc.
In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 926617 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY112.2%
TTM net income YoY55.8%
TTM EPS YoY71.4%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—
Margins
Gross margin1,481.2%
Operating margin-2,079.9%
Net margin-1,520.4%
FCF margin—
EBITDA margin-2,026.1%
Returns
ROE—
ROA-87.8%
ROIC (approx.)—
Asset turnover0.06x
Leverage & solvency
Liabilities / assets291.9%
Debt / equity—
Current ratio0.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.08x
Accruals ratio6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11,000 | $17,000 | $32,000 | $254,000 | $89,000 | $169,000 | $0 | -$2.83M |
| Cost of revenue | $869,000 | $915,000 | $896,000 | $790,000 | $922,000 | $870,000 | $719,000 | $860,000 |
| Gross profit | $1.01M | $1.13M | $1.07M | $1.44M | $1.38M | $1.53M | $1.56M | $1.49M |
| R&D expense | $589,000 | $692,000 | $1.23M | $462,000 | $739,000 | $704,000 | $973,000 | $500,000 |
| SG&A expense | $1.15M | $1.71M | $1.50M | $1.72M | $1.54M | $1.96M | $2.74M | $2.44M |
| Operating income | -$1.21M | -$1.83M | -$2.20M | -$1.28M | -$1.58M | -$1.81M | -$3.24M | -$3.43M |
| Pretax income | $339,000 | — | $676,000 | -$3.37M | -$4.89M | — | -$1.85M | — |
| Net income | $339,000 | -$2.42M | $676,000 | -$3.37M | -$4.89M | -$2.67M | -$1.85M | -$1.39M |
| EBITDA | -$1.16M | -$1.79M | -$2.16M | -$1.25M | -$1.53M | -$1.80M | -$3.23M | -$3.42M |
| EPS (basic) | 0.01 | -0.05 | 0.02 | — | -0.13 | -0.07 | -0.09 | — |
| EPS (diluted) | 0.01 | -0.05 | -0.05 | — | -0.13 | -0.07 | -0.09 | — |
| Weighted avg. shares (diluted) | 47.58M | 44.25M | 45.77M | — | 36.39M | 35.56M | 21.59M | — |
| Banking | ||||||||
| Net interest income | -$330,000 | -$227,000 | -$231,000 | -$1,000 | -$13,000 | -$13,000 | -$14,000 | -$13,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $12,000 | $477,000 | $1.34M | $1.75M | $3.81M | $1.54M | $3.31M | $1.77M |
| Receivables | $1.44M | $1.49M | $1.42M | $1.21M | $1.32M | $1.28M | $1.10M | $990,000 |
| Inventory | $229,000 | $231,000 | $292,000 | $256,000 | $282,000 | $273,000 | $260,000 | $326,000 |
| Current assets | $1.85M | $2.80M | $3.79M | $4.06M | $5.83M | $3.69M | $5.39M | $4.18M |
| PP&E, net | $367,000 | $179,000 | $38,000 | $47,000 | $44,000 | $44,000 | $56,000 | $69,000 |
| Intangibles | $214,000 | $246,000 | $278,000 | $310,000 | $343,000 | — | — | — |
| Total assets | $3.58M | $4.43M | $5.09M | $5.46M | $7.30M | $4.93M | $6.72M | $5.49M |
| Current liabilities | $6.09M | $5.34M | $5.59M | $3.46M | $4.20M | $4.10M | $3.79M | $5.47M |
| Short-term debt | $152,000 | $199,000 | $238,000 | $236,000 | $234,000 | $232,000 | $231,000 | $229,000 |
| Long-term debt | $948,000 | $961,000 | $980,000 | $1.04M | $1.10M | $1.16M | $1.22M | $1.28M |
| Total debt | $1.10M | $1.16M | $1.22M | $1.28M | $1.33M | $1.39M | $1.45M | $1.51M |
| Total liabilities | $10.45M | $11.69M | $11.29M | $12.39M | $11.64M | $7.62M | $6.78M | $8.05M |
| Shareholders' equity | -$6.87M | -$7.26M | -$6.21M | -$6.93M | -$4.34M | -$2.69M | -$60,000 | -$2.56M |
| Net debt | $1.09M | $683,000 | -$126,000 | -$478,000 | -$2.48M | -$153,000 | -$1.86M | -$262,000 |
| Shares outstanding | 46.63M | 46.63M | 43.50M | 43.48M | 42.66M | 35.64M | 35.23M | 17.41M |
| Cash flow statement | ||||||||
| Operating cash flow | -$794,000 | -$2.01M | -$359,000 | -$1.98M | -$212,000 | -$1.73M | -$3.10M | -$1.02M |
| Capital expenditure | $207,000 | — | — | $8,000 | — | — | — | $0 |
| Free cash flow | -$1.00M | — | — | -$1.99M | — | — | — | -$1.02M |
| Investing cash flow | -$207,000 | — | — | -$8,000 | — | — | — | $0 |
| Financing cash flow | $536,000 | $1.29M | -$52,000 | -$65,000 | $2.87M | -$33,000 | $4.64M | $657,000 |
| Depreciation & amortization | $51,000 | $40,000 | $40,000 | $38,000 | $50,000 | $11,000 | $13,000 | $14,000 |
| Stock-based compensation | $50,000 | $19,000 | $42,000 | $376,000 | $37,000 | $15,000 | $103,000 | $630,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.